RESUMEN
BACKGROUND: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. OBJECTIVES: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. METHODS: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). RESULTS: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. CONCLUSIONS: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
Asunto(s)
Inmunoconjugados , Linfoma Cutáneo de Células T , Trastornos Linfoproliferativos , Micosis Fungoide , Síndrome de Sézary , Neoplasias Cutáneas , Femenino , Humanos , Persona de Mediana Edad , Brentuximab Vedotina/uso terapéutico , Inmunoconjugados/efectos adversos , Neoplasias Cutáneas/patología , Micosis Fungoide/patología , Síndrome de Sézary/patología , Sistema de Registros , Antígeno Ki-1RESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Anciano , Sarcoidosis/diagnóstico , Tejido de Granulación/patología , Cicatrización de Heridas , Punciones/efectos adversos , Dermatitis/etiologíaAsunto(s)
Cicatriz/complicaciones , Sarcoidosis/diagnóstico , Enfermedades de la Piel/diagnóstico , Anciano , Femenino , Humanos , Inyecciones Intravenosas , Inyecciones Subcutáneas , Sarcoidosis/etiología , Sarcoidosis/patología , Enfermedades de la Piel/etiología , Enfermedades de la Piel/patologíaRESUMEN
Introducción y objetivos: El linfoma B cutáneo primario (LBCP) es una neoplasia de muy baja prevalencia y supone un 25% de todos los linfomas cutáneos. Nuestro objetivo era conocer las características epidemiológicas, clínicas e histológicas de los LBCP de nuestra área sanitaria. Métodos: Estudio descriptivo retrospectivo con datos de los pacientes con diagnóstico anatomopatológico de LBCP seguidos entre los años 2004 y 2015 en el Hospital Universitario Virgen del Rocío. Resultados: Se incluyeron 22 casos de pacientes con LBCP. El 65% eran varones frente a un 35% de mujeres. El linfoma centrofolicular supuso el subtipo más frecuente (41%). Tres casos desarrollaron afectación ganglionar y uno, invasión de la médula ósea. Durante el seguimiento se observaron 5 recidivas y un paciente falleció a causa de su LBCP. Discusión y conclusiones: Aportamos una de las primeras series de pacientes con LBCP descritas en población española. La incidencia detectada en nuestra área es similar a las de otras poblaciones descritas en la literatura. Respecto al sexo, la edad, la distribución por subtipos y la presentación clínica e inmunohistoquímica, también se obtuvieron datos similares a los de otras series (AU)
Introduction and objectives: Primary cutaneous B-cell lymphoma (CBCL) is a very low prevalence neoplasm and constitutes 25% of all primary cutaneous lymphomas. Our objective was to discover the epidemiological, clinic and histologic characteristics of CBCL in our area. Methods: Retrospective descriptive study with patients with histologic diagnosis of CBCL followed up in our department between 2004 and 2015. Results: Twenty-two patients with CBCL were included; 65% were men and 35% were women. Follicle centre lymphoma was the most common subtype (41%). Only 3 cases presented with node involvement and one with bone marrow invasion. Five recurrences were detected and one patient died because of the CBCL. Discussion and conclusions: This is one of the first CBCL series in theSpanish population. The incidence, sex, age, subtype distribution, clinical features and immunohistochemical patterns are very similar to those of the other series (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Linfoma de Células B/complicaciones , Linfoma de Células B/epidemiología , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/epidemiología , Linfoma de Células B Grandes Difuso/complicaciones , Linfoma de Células B Grandes Difuso/epidemiología , Linfoma de Células B Grandes Difuso/patología , Estudios Retrospectivos , Inmunohistoquímica/métodos , InmunohistoquímicaRESUMEN
INTRODUCTION AND OBJECTIVES: Primary cutaneous B-cell lymphoma (CBCL) is a very low prevalence neoplasm and constitutes 25% of all primary cutaneous lymphomas. Our objective was to discover the epidemiological, clinic and histologic characteristics of CBCL in our area. METHODS: Retrospective descriptive study with patients with histologic diagnosis of CBCL followed up in our department between 2004 and 2015. RESULTS: Twenty-two patients with CBCL were included; 65% were men and 35% were women. Follicle centre lymphoma was the most common subtype (41%). Only 3 cases presented with node involvement and one with bone marrow invasion. Five recurrences were detected and one patient died because of the CBCL. DISCUSSION AND CONCLUSIONS: This is one of the first CBCL series in theSpanish population. The incidence, sex, age, subtype distribution, clinical features and immunohistochemical patterns are very similar to those of the other series.